A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Blood Adv. 2022 Jul 26;6(14):4224-4227. doi: 10.1182/bloodadvances.2022007854.

Abstract

  1. Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia.

  2. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

Publication types

  • Multicenter Study

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Cladribine / therapeutic use
  • Humans
  • Leukemia, Hairy Cell* / drug therapy
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Cladribine